URLC10 + VEGFR1 + VEGFR2 peptide vaccine (University of Tokyo)

The URLC10 + VEGFR1 + VEGFR2 peptide vaccine is a therapeutic cancer vaccine developed by the University of Tokyo and OncoTherapy Science for the treatment of advanced non-small cell lung cancer (NSCLC). The vaccine consists of three synthetic peptides—URLC10-611, VEGFR1-1084, and VEGFR2-169—which are restricted to the HLA-A*2402 allele. By targeting URLC10, a cancer-testis antigen highly expressed in lung cancer, and the vascular endothelial growth factor receptors 1 and 2 (VEGFR1/2) expressed on tumor-associated endothelial cells, the vaccine aims to induce a robust cytotoxic T-lymphocyte (CTL) response that simultaneously attacks the tumor cells and inhibits tumor-induced angiogenesis. Clinical evaluation has primarily focused on patients with refractory NSCLC who have failed standard chemotherapy, often administered in combination with incomplete Freund's adjuvant.

Other names

URLC10, VEGFR1, and VEGFR2 Peptide Vaccinemultiple-peptide vaccine (URLC10, VEGFR1, VEGFR2)